The Sixth Edition of the Biosafety in Microbiological and Biomedical Laboratories (BMBL) manual emphasizes the importance of risk assessment and management, communication among all stakeholders, comprehensive procedures to report accidents and exposures, and a new focus on biocontainment of pathogens affecting agricultural animals. First published in 1984, the BMBL still serves as the cornerstone of biosafety practices for the safe conduct of research throughout the world.

The unprecedented health and economic impact of the COVID-19 pandemic is driving many institutions to increase investment in new biocontainment facilities or rapidly pivot to upgrade and repurpose existing containment spaces in an urgent attempt to respond to the crisis. Hundreds of organizations nationwide began applying for grants after the National Institutes for Health (NIH) received $3.6 billion in funding dedicated to COVID-19 research as part of an emergency stimulus bill passed earlier this year. The NIH now has until 2024 to release the funds. Additionally, private donors, non-governmental organizations, and other entities worldwide are providing billions in funding for development of testing and vaccine programs. This surge of financing is expected to fuel a growth in the creation of new biocontainment spaces in the near future and long term. Since designing, building, and commissioning new biocontainment labs is an expensive and time-consuming process, some institutions are electing to upgrade existing BSL-2 facilities to make them BSL-3, while others are choosing to move existing research programs to make room for new pandemic-related initiatives.